Adjunctive Use of Apyrase to Fibrinolytic Therapy

Award Information

Agency: Department of Health and Human Services	Branch: N/A	Award ID: 93933	Program Year/Program: 2009 / SBIR
Agency Tracking Number: HL095169	Solicitation Year: N/A	Solicitation Topic Code: N/A	Solicitation Number: N/A

Small Business Information: APT THERAPEUTICS, INC.
4041 Forest Park Avenue SAINT LOUIS, MO 63108-
View profile »

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No

Phase 1: Fiscal Year: 2009

Title: Adjunctive Use of Apyrase to Fibrinolytic Therapy

Agency: HHS

Contract: 1R43HL095169-01A1

Award Amount: $226,120.00

Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I grant support, we will determine whether optimized human apyrases, in combination with tPA, induce rapid and sustain ed coronary artery recanalization without increasing bleeding risk. PUBLIC HEALTH RELEVANCE: We will utilize a coronary thrombotic model in dogs to validate whether human apyrase more effectively improve coronary patency than clopidogrel without increasing bleeding risk.

Principal Investigator:
Ridong Chen
3146086932
RCHEN@NIDUSCENTER.COM

Business Contact:
Ridong Chen
rchen@niduscenter.com

Small Business Information at Submission:

APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD SAINT LOUIS, MO 63141

EIN/Tax ID: 431947715

DUNS: N/A

Number of Employees: N/A

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No